In vivo functional dissection of a context-dependent role for Hif1 alpha in pancreatic tumorigenesis

Creative Commons License

Cheng T., Jian Z., Li K., Raulefs S., Regel I., Shen S., ...More

ONCOGENESIS, vol.5, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2016
  • Doi Number: 10.1038/oncsis.2016.78
  • Journal Name: ONCOGENESIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Hypoxia-inducible factor 1 alpha (Hif1 alpha) is a key regulator of cellular adaptation and survival under hypoxic conditions. In pancreatic ductal adenocarcinoma (PDAC), it has been recently shown that genetic ablation of Hif1 alpha accelerates tumour development by promoting tumour-supportive inflammation in mice, questioning its role as the key downstream target of many oncogenic signals of PDAC. Likely, Hif1 alpha has a context-dependent role in pancreatic tumorigenesis. To further analyse this, murine PDAC cell lines with reduced Hif1 alpha expression were generated using shRNA transfection. Cells were transplanted into wild-type mice through orthotopic or portal vein injection in order to test the in vivo function of Hif1 alpha in two major tumour-associated biological scenarios: primary tumour growth and remote colonization/metastasis. Although Hif1 alpha protects PDAC cells from stress-induced cell deaths in both scenarios-in line with the general function Hif1 alpha-its depletion leads to different oncogenic consequences. Hif1 alpha depletion results in rapid tumour growth with marked hypoxia-induced cell death, which potentially leads to a persistent tumour-sustaining inflammatory response. However, it simultaneously reduces tumour colonization and hepatic metastases by increasing the susceptibility to anoikis induced by anchorage-independent conditions. Taken together, the role of Hif1 alpha in pancreatic tumorigenesis is context-dependent. Clinical trials of Hif1 alpha inhibitors need to take this into account, targeting the appropriate scenario, for example palliative vs adjuvant therapy.